The role of mTOR inhibitors in the prevention of organ rejection in adult liver transplant patients: a focus on everolimus

References

• Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19(1):3–26.
   PubMed Web of Science ®Google Scholar
• Selzner N, Grant DR, Shalev I, Levy GA. The immunosuppressive pipeline: meeting unmet needs in liver transplantation. Liver Transpl. 2010;16(12):1359–1372.
   Web of Science ®Google Scholar
• Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med. 2005;352(13):1371–1373.
   Web of Science ®Google Scholar
• Campbell MS, Rai J, Kozin E, et al. Effects of sirolimus vs calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. Clin Transplant. 2007;21(3):377–384.
   Web of Science ®Google Scholar
• Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931–940.
   PubMed Web of Science ®Google Scholar
• Györi GP, Silberhumer GR, Zehetmayer S, et al. Dynamic changes in MELD score not only predict survival on the waiting list but also overall survival after liver transplantation. Transpl Int. 2012;25(9):935–940.
   Web of Science ®Google Scholar
• Cholongitas E, Marelli L, Shusang V, et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl. 2006;12(7):1049–1061.
   PubMed Web of Science ®Google Scholar
• Dutkowski P, Oberkofler C E, Béchir M, et al. The model for end-stage liver disease allocation system for liver transplantation saves lives, but increases morbidity and cost: a prospective outcome analysis. Liver Transpl. 2011;17(6):674–684.
   PubMed Web of Science ®Google Scholar
• Pillai AA, Levitsky J. Overview of immunosuppression in liver transplantation. World J Gastroenterol. 2009;15(34):4225–4233.
   Web of Science ®Google Scholar
• Kawahara T, Asthana S, Kneteman N. m-TOR inhibitors: what role in liver transplantation? J Hepatol. 2011;55(6):1441–1451.
   PubMed Web of Science ®Google Scholar
• Campsen J, Zimmerman MA, Mandell S, Kaplan M, Kam I. A decade of experience using mTor inhibitors in liver transplantation. J Transplant. 2011;2011:913094.
   Google Scholar
• Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant. 2008;22(1):1–15.
   Web of Science ®Google Scholar
• De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012;12(11):3008–3020.
   PubMed Web of Science ®Google Scholar
• Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803–2835.
   PubMed Web of Science ®Google Scholar
• Reich DJ, Clavien PA, Hodge EE. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation. 2005;80(1):18–25.
   Web of Science ®Google Scholar
• Cantarovich M, Tzimas GN, Barkun J, et al. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation. 2003;76(1):98–102.
   Web of Science ®Google Scholar
• Teperman L, Moonka D, Sebastian A, et al. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl. 2013;19(7):675–689.
   PubMed Web of Science ®Google Scholar
• Trotter JF, Grafals M, Alsina AE. Early use of renal-sparing agents in liver transplantation: a closer look. Liver Transpl. 2013;19(8):826–842.
   PubMed Web of Science ®Google Scholar
• Chandok N, Watt KD. Burden of de novo malignancy in the liver transplant recipient. Liver Transpl. 2012;18(11):1277–1289.
   Web of Science ®Google Scholar
• Tan HP, Basu A, Shapiro R. Everolimus: an update. Curr Opin Organ Transpl. 2003;8(4):323–326.
   Google Scholar
• Mehrabi A, Fonouni H, Kashfi A, et al. The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant. 2006;20 Suppl 17:30–43.
   Google Scholar
• McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl. 2001;7(8):701–708.
   Web of Science ®Google Scholar
• Macdonald AS. Use of mTOR inhibitors in human organ transplantation. Expert Rev Clin Immunol. 2007;3(3):423–436.
   PubMedGoogle Scholar
• Khan S, Sewell WA. Oral immunosuppressive drugs. Clin Med. 2006;6(4):352–355.
   Web of Science ®Google Scholar
• Kovarik JM, Curtis JJ, Hricik DE, et al. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc. 2006;38(10):3456–3458.
   Web of Science ®Google Scholar
• Lamoureux F, Picard N, Boussera B, Sauvage FL, Marquet P. Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus. Fundam Clin Pharmacol. 2012;26(4):463–472.
   PubMed Web of Science ®Google Scholar
• Keating GM, Lyseng-Williamson KA. Everolimus: a guide to its use in liver transplantation. Bio Drugs. 2013;27(4):407–411.
   Google Scholar
• Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy. 2010;30(10):1044–1056.
   PubMed Web of Science ®Google Scholar
• Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43(2):83–95.
   PubMed Web of Science ®Google Scholar
• Budde K, Neumayer HH, Lehne G, et al; RADW 102 Renal Transplant Study Group. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. Nephrol Dial Transplant. 2004;19(10):2606–2614.
   Web of Science ®Google Scholar
• Peveling-Oberhag J, Zeuzem S, Yong WP, et al. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study. Clin Ther. 2013;35(3):215–225.
   PubMed Web of Science ®Google Scholar
• Kirchner GI, Winkler M, Mueller L, et al. Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br J Clin Pharmacol. 2000;50(5):449–454.
   PubMed Web of Science ®Google Scholar
• Kuypers DR. Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Ann Transplant. 2008; 13(3):11–18.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Mukherjee U. A comprehensive review of immunosuppression used for liver transplantation. J Transplant. 2009;2009:701464.
   Google Scholar
• Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation. 2004;77(10):1555–1561.
   PubMed Web of Science ®Google Scholar
• Weir MR, Diekmann F, Flechner SM, et al. mTOR inhibition: the learning curve in kidney transplantation. Transpl Int. 2010;23(5):447–460.
   Web of Science ®Google Scholar
• Haydar AA, Denton M, West A, Rees J, Goldsmith DJ. Sirolimus-induced pneumonitis: three cases and a review of the literature. Am J Transplant. 2004;4(1):137–139.
   Web of Science ®Google Scholar
• Zuckermann A, Wang SS, Epailly E, et al. Everolimus immunosuppression in de novo heart transplant recipients: what does the evidence tell us now? Transplant Rev (Orlando). 2013;27(3):76–84.
   Google Scholar
• Harper SJ, Gelson W, Harper IG, Alexander GJ, Gibbs P. Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: a single-center experience. Transplantation. 2011;91(1):128–132.
   Web of Science ®Google Scholar
• Watson CJ, Friend PJ, Jamieson NV, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation. 1999;67(4):505–509.
   Web of Science ®Google Scholar
• Chang GJ, Mahanty HD, Quan D, et al. Experience with the use of sirolimus in liver transplantation – use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl. 2000;6(6):734–740.
   Web of Science ®Google Scholar
• Kniepeiss D, Iberer F, Schaffellner S, et al. Nonnephrotoxic immunosuppression in patients after liver transplantation. Int Immunopharmacol. 2005;5(1):133–136.
   Web of Science ®Google Scholar
• Zimmerman MA, Trotter JF, Wachs M, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl. 2008;14(5):633–638.
   PubMed Web of Science ®Google Scholar
• Di Benedetto F, Di Sandro S, De Ruvo N, et al. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors. J Clin Gastroenterol. 2009;43(3):280–286.
   Web of Science ®Google Scholar
• Lam P, Yoshida A, Brown K, et al. The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Dig Dis Sci. 2004;49(6):1029–1035.
   Web of Science ®Google Scholar
• Campsen J, Zimmerman MA, Mandell S, Kaplan M, Kam I. A decade of experience using mTor inhibitors in liver transplantation. J Transplant. 2011;2011:913094.
   Google Scholar
• Kahan BD, Wong RL, Carter C, et al. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation. 1999;68(8):1100–1106.
   PubMed Web of Science ®Google Scholar
• Kahan BD, Kaplan B, Lorber MI, et al. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation. 2001;71(10):1400–1406.
   PubMed Web of Science ®Google Scholar
• Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant. 2004(4);4:626–635.
   Google Scholar
• Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349(9):847–858.
   PubMed Web of Science ®Google Scholar
• Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation. 2004;78(9):1332–1340.
   PubMed Web of Science ®Google Scholar
• Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transpl. 2010;10(6):1401–1413.
   PubMed Web of Science ®Google Scholar
• Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. 2006;12(11):1640–1648.
   PubMed Web of Science ®Google Scholar
• Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation – PROTECT. Am J Transplant. 2012;12(7):1855–1865.
   PubMed Web of Science ®Google Scholar
• Masetti M, Montalti M, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transpl. 2010;10(10):2252–2262.
   PubMed Web of Science ®Google Scholar
• Saliba F, De Simone P, Nevens F, et al; H2304 Study Group. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transpl. 2013;13(7):1734–1745.
   PubMed Web of Science ®Google Scholar
• Sterneck M, Kaiser GM, Heyne N, et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transpl. 2014;14(3):701–710.
   PubMed Web of Science ®Google Scholar
• Peddi VR, Wiseman A, Chavin K, Slakey D. Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev (Orlando). 2013;27(4):97–107.
   PubMedGoogle Scholar
• De Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl. 2009;15(10):1262–1269.
   PubMed Web of Science ®Google Scholar
• Saliba F, Dharancy S, Lorho R, et al. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl. 2011;17(8):905–913.
   Web of Science ®Google Scholar
• Castroagudin JF, Molina E, Romero R, et al. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl. 2009;15(12):1792–1797.
   Web of Science ®Google Scholar
• Casanovas T, Argudo A, Peña-Cala MC. Everolimus in clinical practice in long-term liver transplantation: an observational study. Transplant Proc. 2011;43(6):2216–2219.
   Web of Science ®Google Scholar
• Balderramo D, Prieto J, Cárdenas A, Navasa M. Hepatic encephalopathy and posttransplant hyponatremia predict early calcineurin inhibitor-induced neurotoxicity after liver transplantation. Transpl Int. 2011;24(8):812–819.
   Web of Science ®Google Scholar
• Kamdar KY, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant. 2011;16(3):274–280.
   PubMed Web of Science ®Google Scholar
• Parker R, Oo YH, Adams DH. Management of patients with difficult autoimmune hepatitis. Therap Adv Gastroenterol. 2012;5(6):421–437.
   Web of Science ®Google Scholar
• Casanovas T, Argudo A, Peña-Cala MC. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports. Transplant Proc. 2011;43(6):2233–2236.
   Web of Science ®Google Scholar
• Merli M, Gentili F, Giusto M, et al. Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis? Dig Liver Dis. 2009;41(5):345–349.
   Google Scholar
• Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant. 2011;11(11):2453–2462.
   PubMedGoogle Scholar
• Villamil FG, Gadano AC, Zingale F, et al; REVERT Study Group. Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs calcineurin inhibitors. Liver Int. Epub December 15, 2013. DOI:10.1111/liv.12416.
   Google Scholar
• Junge G, Dumortier T, Schwende H, Fung J. mTOR inhibition in liver transplantation: how to dose for effective/safe CNI reduction? Transplant Proc. 2013;45(5):1979–1980.
   Web of Science ®Google Scholar
• Hirt SW, Bara C, Barten MJ, et al. Everolimus in heart transplantation: an update. J Transplant. 2013;2013:683964.
   Google Scholar
• Alegre C, Jiménez C, Manrique A, et al. Everolimus monotherapy or combined therapy in liver transplantation: indications and results. Transplant Proc. 2013;45(5):1971–1974.
   Web of Science ®Google Scholar